Transfer studies of polystyrene nanoparticles in the ex vivo human placenta perfusion model: key sources of artifacts

References

• RiehemannK 2009 Nanomedicine-challenge and perspectives Angew. Chem. Int. Edn 48 872 897 872–97 10.1002/anie.200802585
   PubMed Web of Science ®Google Scholar
• WickP 2014 Advanced human in vitro models to assess metal oxide nanoparticle-cell interactions MRS Bull. 39 984 989 984–9 10.1557/mrs.2014.219
   Web of Science ®Google Scholar
• KreylingW GHirnSSchlehC 2010 Nanoparticles in the lung Nat. Biotechnol. 28 1275 1276 1275–6 10.1038/nbt.1735
   PubMed Web of Science ®Google Scholar
• NelA E 2009 Understanding biophysicochemical interactions at the nano-bio interface Nat. Mater. 8 543 557 543–57 10.1038/nmat2442
   PubMed Web of Science ®Google Scholar
• LundqvistM 2008 Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl Acad. Sci. USA 105 14265 14270 14265–70 10.1073/pnas.0805135105
   PubMed Web of Science ®Google Scholar
• CristR M 2013 Common pitfalls in nanotechnology: lessons learned from NCI’s nanotechnology characterization laboratory Integr. Biol. 5 66 73 66–73 10.1039/C2IB20117H
   Google Scholar
• WarheitD B 2008 How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization? Toxicol. Sci. 101 183 185 183–5 10.1093/toxsci/kfm279
   PubMed Web of Science ®Google Scholar
• European Chemicals Agency (ECHA) 2012 Guidance on information requirements and chemical safety assessment appendix R7-1 Recommendations for nanomaterials applicable to chapter R7a—Endpoint specific guidance—ECHA-12-G-EN. 30-4-2012
   Google Scholar
• OECD 2009 Guidance manual for the testing of manufactured nanomaterials: OECD’s sponsorship program. First revision ENV/JM/MONO(2009)20/REV
   Google Scholar
• HoleP 2013 Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA) J. Nanopart. Res. 15 2101 10.1007/s11051-013-2101-8
   PubMed Web of Science ®Google Scholar
• WickP Barrier capacity of human placenta for nanosized material Environ. Health Perspect 118 432 436 432–6 10.1289/ehp.0901200
   PubMed Web of Science ®Google Scholar
• GrafmullerS 2013 Determination of the transport rate of xenobiotics and nanomaterials across the placenta using the ex vivo human placental perfusion model J. Vis. Exp. 76 e50401 10.3791/50401
   Google Scholar
• HwangM NEdererG M 1975 Rapid hippurate hydrolysis method for presumptive identification of group B streptococci J. Clin. Microbiol. 1 114 115 114–5
   PubMed Web of Science ®Google Scholar
• ZhengJ 2011 Sterilization of silver nanoparticles using standard gamma irradiation procedure affects particle integrity and biocompatibility J. Nanomed. Nanotechnol. S5 001 10.4172/2157-7439.S5-001
   Google Scholar
• OberdorsterG 2005 Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy Part. Fibre Toxicol. 2 8 10.1186/1743-8977-2-8
   PubMed Web of Science ®Google Scholar
• PietzonkaP 2002 Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake Pharm. Res. 19 595 601 595–601 10.1023/A:1015393710253
   PubMed Web of Science ®Google Scholar
• SalvatiA 2011 Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics Nanomedicine 7 818 826 818–26 10.1016/j.nano.2011.03.005
   PubMed Web of Science ®Google Scholar
• TenutaT 2011 Elution of labile fluorescent dye from nanoparticles during biological use PLoS One 6 e25556 10.1371/journal.pone.0025556
   PubMed Web of Science ®Google Scholar
• MahonEHristovD RDawsonK A 2012 Stabilising fluorescent silica nanoparticles against dissolution effects for biological studies Chem. Commun. 48 7970 7972 7970–2 10.1039/c2cc34023b
   PubMed Web of Science ®Google Scholar
• MenezesVMalekAKeelanJ A 2011 Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure Curr. Pharm. Biotechnol. 12 731 742 731–42 10.2174/138920111795471010
   PubMed Web of Science ®Google Scholar
• SymeM RPaxtonJ WKeelanJ A 2004 Drug transfer and metabolism by the human placenta Clin. Pharmacokinet. 43 487 514 487–514 10.2165/00003088-200443080-00001
   PubMed Web of Science ®Google Scholar
• ProuillacCLecoeurS 2010 The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies Drug Metab. Dispos. 38 1623 1635 1623–35 10.1124/dmd.110.033571
   PubMed Web of Science ®Google Scholar
• AyeI LKeelanJ A 2013 Placental ABC transporters, cellular toxicity and stress in pregnancy Chem. Biol. Interact. 203 456 466 456–66 10.1016/j.cbi.2013.03.007
   PubMed Web of Science ®Google Scholar
• KonduruN 2014 Biokinetics and effects of barium sulfate nanoparticles Part. Fibre Toxicol. 11 55 70 55–70 10.1186/s12989-014-0055-3
   PubMed Web of Science ®Google Scholar
• BruininkAWangJWickP 2015 Effect of particle agglomeration in nanotoxicology Arch. Toxicol. 89 659 675 659–75 10.1007/s00204-015-1460-6
   PubMed Web of Science ®Google Scholar